Direct targeting of EphA2 and its subsequent inhibition in gastric cancer and other tumor types (e.g., colorectal cancer) has been already successfully achieved to control Wnt-dependent, EphA2-mediated tumor proliferation (Huang et al., 2017). This evidence concerns the gene EPHA2 and neoplasm.